15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $62.6B | $7.8B | 74.3% | 0.0% | $9.1B | $64.6B | $1.1B |
| 2024 | $63.6B | $8.0B | 71.9% | 0.0% | $9.8B | $63.6B | $1.0B |
| 2023 | $59.6B | $2.1B | 58.1% | 0.0% | $4.8B | $71.8B | $2.9B |
| 2022 | $101.2B | $31.4B | 66.1% | 0.0% | $26.0B | $35.4B | $416M |
| 2021 | $81.3B | $22.0B | 62.1% | 0.0% | $29.9B | $37.8B | $1.9B |
| 2020 | $41.7B | $9.2B | 79.6% | 0.0% | $12.2B | $4.6B | $1.8B |
| 2019 | — | $16.0B | — | — | $10.5B | $51.3B | $1.1B |
| 2018 | — | $11.2B | — | — | $13.8B | $40.8B | $1.1B |
| 2017 | — | $21.3B | — | — | $14.8B | $43.2B | $1.3B |
| 2016 | — | $7.2B | — | — | $14.4B | $37.2B | $2.6B |
| 2015 | — | $7.0B | — | — | $13.3B | $28.8B | $3.6B |
| 2014 | — | $9.1B | — | — | $15.9B | $31.5B | $3.3B |
| 2013 | — | $22.0B | — | — | $16.5B | $35.5B | $2.2B |
| 2012 | — | $14.6B | — | — | $15.4B | $36.2B | $10.1B |
| 2011 | — | $10.0B | — | — | $18.6B | $34.9B | $3.2B |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $14.5B | $2.7B | 75.4% | 0.0% | $2.2B | $64.4B | $1.7B |
| Dec '25 | $17.6B | -$1.6B | 70.0% | 0.0% | $4.5B | $64.6B | $1.1B |
| Sep '25 | $16.7B | $3.5B | 74.9% | 0.0% | $4.0B | $61.7B | $1.3B |
| Jun '25 | $14.7B | $2.9B | 74.2% | 0.0% | -$1.2B | $61.7B | $1.6B |
| Mar '25 | $13.7B | $3.0B | 79.3% | 0.0% | $1.8B | $61.5B | $1.4B |
| Dec '24 | $17.8B | $410M | 66.7% | 0.0% | $5.8B | $63.6B | $1.0B |
| Sep '24 | $17.7B | $4.5B | 70.3% | 0.0% | $6.1B | $67.6B | $1.1B |
| Jun '24 | $13.3B | $41M | 75.2% | 0.0% | -$2.4B | $69.2B | $1.1B |
| Mar '24 | $14.9B | $3.1B | 77.3% | 0.0% | $386M | $69.2B | $719M |
| Dec '23 | $14.6B | -$3.4B | 48.1% | 0.0% | $4.2B | $71.8B | $2.9B |
| Oct '23 | $13.5B | -$2.4B | 31.3% | 0.0% | $2.6B | $63.3B | $3.1B |
| Jul '23 | $13.0B | $2.3B | 75.1% | 0.0% | -$2.1B | $64.9B | $2.6B |
| Apr '23 | $18.5B | $5.5B | 73.6% | 0.0% | $73M | $35.3B | $2.2B |
| Dec '22 | $24.3B | $5.0B | 60.3% | 0.0% | $7.6B | $35.4B | $416M |
| Oct '22 | $22.6B | $8.6B | 73.2% | 0.0% | $5.1B | $35.2B | $1.3B |
| Jul '22 | $27.7B | $9.9B | 68.8% | 0.0% | $7.4B | $35.6B | $1.8B |
| Apr '22 | $25.7B | $7.9B | 61.1% | 0.0% | $5.9B | $35.9B | $2.5B |
| Dec '21 | — | $3.4B | — | — | $4.9B | $37.8B | $1.9B |
| Oct '21 | — | $8.1B | — | — | $10.2B | $39.0B | $2.0B |
| Jul '21 | — | $5.6B | — | — | $10.8B | $39.1B | $2.4B |
How the market has priced PFE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Pfizer's revenue has grown 8.5% per year, and net income declined 3.2% per year. These are computed facts, not advice.
As of FY2025, Pfizer reported $64.6B of total debt against $1.1B of cash.
In FY2025, gross margin was 74.3%, operating margin —, and net margin 12.4%.
As of Jun '26, Pfizer traded at a price-to-earnings ratio of about 17.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.